Audit: QRS - Meteoreisen for Health & Longevity

Audit conducted on 26/08/2026 08:42 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol, time, benefit, risk, gate, marker, and qualitative content traces to specific ER passages.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“No controlled trial has tested the preparation itself” and “No trial has timed any response” mirror the ER.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications and cautions retain the ER’s severity classes; “Within hours” is immediately attributed to anthroposophic sources.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications, interactions, benefits, and risks all sit in their ER-native categories.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs or NCT IDs present; WALA, Weleda, and Ferrum sidereum all appear in the ER Therapeutic Protocol for the same facts.
1.6	The QRS does not introduce new attributions.	🟢	Manufacturer, anthroposophic sources, and the palliative-care recommendation are all ER attributions.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured, sceptical register.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Objective throughout while supplying an actionable monitoring panel and decision gates.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents schedules and thresholds as facts of practice, not as orders.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No directive verbs in the document’s own voice.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	“The palliative-care recommendation is…” reports a third-party recommendation rather than issuing one.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Remaining technical terms are ER-native product forms and biomarker names.
2.8	Information is presented in a concise and very compact manner	🟢	Cells and list items are trimmed to the key fact.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text search for “you”/”your”.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Optimal functional ranges and opportunity-cost framing address this audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Full baseline panel and a capped, pre-committed trial assume that willingness.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No general-population simplification or reassurance.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance foregrounds the diagnostic opportunity cost, the decision that matters for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not appear.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“injections”, “hypersensitivity”, “injection-site” used; no consumer-grade substitutes.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings and tier labels match the template byte-for-byte.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 template variables present; marker_#* expanded to 1–8 and qualitative_item# to 1–4.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The website="evidence_review", website="audit", and website="full_review" spans are unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; absent benefit/risk tiers are governed by items 12.5 and 13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard pellet protocol”, “Weleda potency range”, “Best time of day”, “Two-day review rule”, “A capped trial with a pre-committed measure”, “Time to effect”, and all four qualitative labels are verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No invented labels found.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero emoji in the file; the ER’s “⚠️ Conflicted” marker was correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	No rows or cells added beyond the template budget; ER sentences are condensed rather than carried over in full.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Comment opens at line 2, immediately after the doctype.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Entirely inside an HTML comment; no duplicate on-page rendering.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: meteoreisen_2026-0826-0541_Opus_ER.md (line 4).
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02 matches the QRS.md badge version.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0826-0829.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” carries no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Matches the on-disk filename exactly.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Meteoreisen for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Meteoreisen for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0826-0829 → 08/26/2026.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header is the unmodified template structure.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all four Conclusion paragraphs into a single decision-oriented statement.
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Dilution/red blood cell, dosage forms, indications, absence of controlled trials, small direct harm, unexamined treatable cause, and tradition-not-measurement each map to a Conclusion sentence.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “feverish illness”, “low mood”, “sugar pellets” are lay terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial named.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers beyond the qualitative “one red blood cell” comparison.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Drawn from the “Populations who should avoid Meteoreisen” list plus the vaccination/antibiotic absolute contraindication.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five avoid-populations plus substitution for vaccination or antibiotics; six items for six ER entries.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing em-dash rationales (“since tolerated sucrose intake is effectively zero”, “per the manufacturer’s own labelling”) are stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	The 39 °C / 3-day threshold, the full red-flag list, the age-65 cut-off, and the nickel-sensitisation qualifier are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	N/A	The section is populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is populated.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All three items are ER interaction bullets.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Carries the three “Severity: caution” interactions; the vaccination/antibiotic entry is correctly held in Contraindications and the “Severity: none” entries do not change how the intervention is used.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Three <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Severity/consequence/mitigation prose from each ER bullet is stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(paracetamol, ibuprofen, aspirin)” and “(ferrous sulfate, ferrous bisglycinate, iron polymaltose)” retained; disulfiram and metronidazole named.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	N/A	The section is populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is populated.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map to ER Therapeutic Protocol bullets.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose and form, potency range, and timing — the three decisions a user must actually make.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies thirteen protocol bullets; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine variables carry ER-derived content; no placeholders remain.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The 2-day reassessment window, the 2–4 week capped trial, and the “within hours” subjective response are the ER’s only time-anchored response statements.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	The 2-day rule attaches to the Low-tier acute-infection benefit and leads; the two Speculative-tier windows follow.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct aspects exist; all sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine variables carry ER-derived content.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER Practical Considerations section supplies a “Time to effect” bullet.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Both Low and all three Speculative headings are carried across.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Only the ER’s benefit headings appear; the 5.5%-vs-33.6% and odds-ratio magnitudes are omitted.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheticals carried through.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high and benefits_medium carry style="display: none" with no empty-state text.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Medium, Low, and Speculative headings all carried across.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	The 303-million-ampoule magnitude and Louis Bolk attribution are omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheticals carried through.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high carries style="display: none" with no empty-state text.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows mirror the ER Monitoring Protocol & Defining Success table.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER rows present, with target ranges reproduced faithfully.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Baseline, 2-week symptom review, 3-month repeat, annual thereafter, plus the red-flag escalation rule.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Taken from the ER’s “Qualitative markers worth tracking alongside the panel” list.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All four ER qualitative markers present with their bold labels verbatim.

Issues 26/08/2026 08:42

Pass rate 100.00%. No issues found.

Issues 26/08/2026 08:32

1. 1.1 — Garbled time-to-effect sub-line: time_2_sub (line 500) states “A fatigue score recorded at baseline and at the end, ended on a null result”, making the fatigue score the thing that ends; the ER (line 258) says the 2–4 week trial is ended on a null result.
2. 2.8 — Duplicated sentence in Time to effect: time_2_sub (line 500) and time_3_sub (line 511) both close with the identical sentence “No trial has timed any response.”, wasting one-page budget inside a single three-cell row.
3. 2.15 — Colloquial “bloods” in cadence: monitoring_cadence (line 688) says “repeat bloods at 3 months” rather than formal clinical phrasing such as “repeat blood testing at 3 months”.

Fixes 26/08/2026 08:32

1. 1.1 / 2.8 — Time-to-effect sub-line rewritten: time_2_sub changed from “A fatigue score recorded at baseline and at the end, ended on a null result. No trial has timed any response.” to “A capped trial with a fatigue score recorded at baseline and at the end, ended on a null result, prevents indefinite spend.” — restoring the ER’s subject (the trial, not the score) and removing the sentence duplicated in time_3_sub.
2. 2.15 — Colloquial “bloods” replaced: monitoring_cadence changed from “repeat bloods at 3 months” to “repeat blood testing at 3 months”.